A Rollover Study For Subjects Discontinuing From UK-453,061 Studies For The Treatment Of HIV-1

Pfizer logo

Pfizer

Status and phase

Terminated
Phase 2

Conditions

HIV-1

Treatments

Drug: No drug will be administered

Study type

Interventional

Funder types

Industry

Identifiers

NCT00824369
A5271038

Details and patient eligibility

About

The purpose of the protocol is to assess long-term safety and tolerability of subjects who discontinue for any reason from UK-453,061 qualifying studies.

Full description

To assess long term safety and tolerability of subjects who discontinue for any reason from UK-453,061 studies. The study will also assess efficacy of the subsequent regimens in these patients. The trial was terminated prematurely on January 29, 2013, due to the decision of the sponsor to discontinue development of lersivirine. The decision to terminate the trial was not based on any safety or efficacy concerns.

Enrollment

52 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Previous participation in a qualifying study.
  • Male or female at least 18 years of age available for a follow-up period of at least 96 weeks.

Exclusion criteria

  • Concurrent treatment in another clinical trial.
  • Unwilling or unable to be followed for 12 months

Trial design

52 participants in 1 patient group

Anti-retroviral therapy
No Intervention group
Description:
Anti-retroviral therapy
Treatment:
Drug: No drug will be administered

Trial contacts and locations

27

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems